Company / Return on Equity (ROE)
Neurocrine Biosciences Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
14.7%
FY2025
5-year range
6.5% / 36.2%
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
#29 of 190
Health Care
What the data says
Neurocrine Biosciences's return on equity (roe) of 14.7% is higher than 85% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -44.8% in FY2016 to 36.2% in FY2022.
Based on SEC 10-K filings.
14.7% in FY2025 with a 5-year CAGR of -21.5%. Top quartile in the Health Care sector.
Improved from 11.2% to 14.7% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -21.5pp
- 5-Year Change
- -21.5pp
- 10-Year Change
- -
Sector benchmark
+129.2% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 11.6% year-over-year.
- Currently 65.1pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 14.7% | +11.6% |
| FY2024 | 13.2% | +17.8% |
| FY2023 | 11.2% | -69.1% |
| FY2022 | 36.2% | +454.8% |
| FY2021 | 6.5% | -82.0% |
| FY2020 | 36.2% | +522.5% |
| FY2019 | 5.8% | +32.3% |
| FY2018 | 4.4% | +111.5% |
| FY2017 | -38.3% | +14.5% |
| FY2016 | -44.8% | -113.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026